TScan Therapeutics, Inc. Quarterly Comprehensive Income (Loss), Net of Tax, Attributable to Parent in USD from Q1 2024 to Q2 2025
-
Taxonomy & unit
-
us-gaap: USD
-
Description
-
Amount after tax of increase (decrease) in equity from transactions and other events and circumstances from net income and other comprehensive income, attributable to parent entity. Excludes changes in equity resulting from investments by owners and distributions to owners.
-
Summary
-
TScan Therapeutics, Inc. quarterly/annual Comprehensive Income (Loss), Net of Tax, Attributable to Parent history and growth rate from Q1 2024 to Q2 2025.
- TScan Therapeutics, Inc. Comprehensive Income (Loss), Net of Tax, Attributable to Parent for the quarter ending June 30, 2025 was -$37M, a 16.7% decline year-over-year.
- TScan Therapeutics, Inc. annual Comprehensive Income (Loss), Net of Tax, Attributable to Parent for 2024 was -$127M, a 42.9% decline from 2023.
Comprehensive Income (Loss), Net of Tax, Attributable to Parent, Quarterly (USD)
Comprehensive Income (Loss), Net of Tax, Attributable to Parent, YoY Quarterly Growth (%)